ENLIVEN THERAPEUTICS, INC. Shareholders' Equity
ENLIVEN THERAPEUTICS, INC. (ELVN) had Shareholders' Equity of $895.15 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-05
- 2026-06-30: Stockholders' Equity Attributable to Parent $895.15M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $453.37M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $459.60M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $476.12M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $895.15M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $453.37M 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $459.60M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $476.12M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $488.47M 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $288.30M 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $309.85M 10-Q · filed 2026-08-05 | |
| 2024-09-30 | $288.40M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $304.93M 10-Q · filed 2025-11-12 | |
| 2024-03-31 | $317.71M 10-Q · filed 2025-11-12 | |
| 2023-12-31 | $245.91M 10-K · filed 2026-03-03 | |
| 2023-09-30 | $261.75M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $278.99M 10-Q · filed 2024-11-13 | |
| 2023-03-31 | $291.42M 10-Q · filed 2024-11-13 | |
| 2022-12-31 | -$76.83M 10-K · filed 2025-03-13 | $90.13M 10-K · filed 2023-02-10 |
| 2022-09-30 | -$68.10M 10-Q · filed 2023-11-09 | $57.29M 10-Q · filed 2022-10-25 |
| 2022-06-30 | -$58.71M 10-Q · filed 2023-11-09 | $61.36M 10-Q · filed 2022-08-03 |
| 2022-03-31 | -$50.61M 10-Q · filed 2023-11-09 | $72.41M 10-Q · filed 2022-05-06 |
| 2021-12-31 | -$42.89M 10-K · filed 2024-03-14 | $86.03M 10-K · filed 2022-03-15 |
| 2021-09-30 | $99.37M 10-Q · filed 2022-10-25 | |
| 2021-06-30 | $64.97M 10-Q · filed 2022-10-25 | |
| 2021-03-31 | $75.59M 10-Q · filed 2022-10-25 | |
| 2020-12-31 | -$20.30M 8-K · filed 2023-06-23 | $84.44M 10-K · filed 2021-03-05 |
| 2020-09-30 | $94.70M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $106.30M 10-Q · filed 2021-11-09 | |
| 2020-03-31 | $105.19M 10-Q · filed 2021-11-09 | |
| 2019-12-31 | -$48.85M 10-K · filed 2022-03-15 | |
| 2019-09-30 | -$41.90M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | -$35.62M 10-Q · filed 2020-11-05 | |
| 2019-03-31 | -$30.41M 10-Q · filed 2020-11-05 | |
| 2018-12-31 | -$26.32M 10-K · filed 2021-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |